Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
18 May 2021Website:
http://oculis.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 01 Jul 2024 20:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
OCS Latest News
ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award.
ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results from its Phase 2b RELIEF trial with licaminlimab, a novel anti-TNFα biologic eye drop with an established dual anti-inflammatory and anti-apoptotic mechanism of action in patients with dry eye disease (DED).
ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the annual equity incentive awards granted to directors of the Company, as well as the one-time equity incentive awards issued to new directors upon their election to the board of directors of the Company.
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting held on May 29, 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST, including election of new members to its Board of Directors, as well as the recent appointment of two new members to its Scientific Advisory Board (SAB), and the establishment of a loan facility of up to CHF 50 million.
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) has recently issued 1,000,000 new registered ordinary shares with a nominal value of CHF 0.01 each, using existing capital reserves. These shares are recorded as treasury shares, bringing the total number of registered shares issued by the Company to 46,443,700, with 41.7 million shares currently outstanding.
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis's management will be attending and presenting at the following upcoming investor conferences:
The consensus price target hints at a 152.8% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Oculis Holding AG (OCS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be attending and presenting at the following upcoming investor conferences:
The consensus price target hints at a 191.3% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What type of business is Oculis Holding AG?
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
What sector is Oculis Holding AG in?
Oculis Holding AG is in the Healthcare sector
What industry is Oculis Holding AG in?
Oculis Holding AG is in the Biotechnology industry
What country is Oculis Holding AG from?
Oculis Holding AG is headquartered in Switzerland
When did Oculis Holding AG go public?
Oculis Holding AG initial public offering (IPO) was on 18 May 2021
What is Oculis Holding AG website?
https://oculis.com
Is Oculis Holding AG in the S&P 500?
No, Oculis Holding AG is not included in the S&P 500 index
Is Oculis Holding AG in the NASDAQ 100?
No, Oculis Holding AG is not included in the NASDAQ 100 index
Is Oculis Holding AG in the Dow Jones?
No, Oculis Holding AG is not included in the Dow Jones index
When does Oculis Holding AG report earnings?
The next expected earnings date for Oculis Holding AG is 08 November 2024